Medindia

X

Frontier Pharma Report: Chronic Obstructive Pulmonary Disease (COPD) Market - Which Molecular Targets Appear Most Frequently in the Pipeline? - Research and Markets

Thursday, April 21, 2016 Respiratory Disease News J E 4
Advertisement

DUBLIN, April 21, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) The current COPD pipeline consists of 212 active products in development. Initial analysis revealed a small presence of first-in-class products, constituting 16.5% of the pipeline. In comparison to other indications, this is relatively low; however, there are some promising trends within COPD product development. The Preclinical Phase of development is the most active in terms of first-in-class products. 

This diminishes throughout clinical development, with only two such products being present in Phase III. However, if either of these products is approved, they would represent the first, first-in-class products to be approved for COPD since roflumilast, which was approved in 2011 by the FDA and in 2010 in the EU. Roflumilast was the first novel therapy for COPD in almost 20 years, which demonstrates the infrequency at which first-in-class products enter the COPD market. So to have two first-in-class products in Phase III and six in Phase II is a promising sign.  Scope: The COPD market has benefited from notable additions in recent years.  - Which classes of drug dominate the market?  - What additional benefits have newly approved therapies brought to market?  - How do the leading marketed therapies compare clinically? 

The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD and novel, first-in-class therapies.  - Which molecular targets appear most frequently in the pipeline?  - To what degree is the pipeline penetrated by first-in-class innovation?  - Which target families consist of the most first-in-class products? 

First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways.  - How well are first-in-class targets aligned to known disease causing pathways?  - Which targets are specifically found in early-stage development?  - What is the industry-wide interest in these targets?  - Which are the most promising first-in-class targets in early-stage development? 

There have been 59 licensing deals and 41 co-development deals pertaining to COPD products since 2006.  - Which territories show the most deal activity?  - What were the trends in deal completion by product stage of development?  - How many deals involved first-in-class products?  - Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?  Key Topics Covered:  1 Table of Contents  1.1 List of Tables  1.2 List of Figures 

2 Executive Summary  2.1 Unmet Needs Remain in COPD Market  2.2 First-in-Class Innovation Beginning to Emerge in COPD  2.3 COPD Lags Behind Asthma in First-in-Class Innovation 

3 The Case for Innovation in COPD  3.1 Growing Number of Opportunities for Biologic Products  3.2 Diversification of Molecular Targets  3.3 Innovative First-in-Class Product Developments Remain Attractive  3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation  3.5 Sustained Innovation  3.6 Research Report Guidance 

4 Clinical and Commercial Landscape  4.1 Disease Overview  4.1.1 Epidemiology  4.1.2 Symptoms  4.1.3 Etiology  4.1.4 Pathophysiology  4.1.5 Diagnosis  4.1.6 Assessment of Disease Severity  4.1.7 Treatment  4.1.8 Treatment Algorithm  4.2 Overview of Marketed Products  4.2.1 Molecule Type and Target Analysis  4.2.2 Quick Relief Medication  4.2.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy  4.2.4 Bronchodilator Monotherapy  4.2.5 Bronchodilator Combination Therapy  4.2.6 Alternative Therapy  4.2.7 Conclusion  4.2.8 Unmet Needs 

5 Assessment of Pipeline Product Innovation  5.1 Molecular Target Analysis  5.2 Comparative Distribution of Programs between COPD Market and Pipeline by Therapeutic Target Family  5.3 First-In-Class Pipeline Programs Targeting Novel Molecular Targets 

6 Signaling Pathways, Disease Causation and Innovation Alignment  6.1 The Complexity of Signaling Networks in COPD  6.2 Signaling Pathways and First-in-Class Molecular Target Integration  6.3 First-in-Class Target Matrix Assessment 

7 First-in-Class Target Evaluation  7.1 Pipeline Programs Targeting Toll-Like Receptor 3  7.2 Pipeline Programs Targeting Adenosine A(2B) Receptor  7.3 Pipeline Programs Targeting Prostaglandin D2 Receptor 2  7.4 Pipeline Programs Targeting P-selectin  7.5 Pipeline Programs Targeting Macrophage Metalloelastase  7.6 Pipeline Programs Targeting Rho Associated Protein Kinase 1  7.7 Pipeline Programs Targeting Soluble Epoxide Hydrolase  7.8 Pipeline Programs Targeting Vasoactive Intestinal Peptide Receptor Family  7.9 Conclusion 

8 Deals and Strategic Consolidations  8.1 Industry-Wide First-in-Class Deals  8.2 Licensing Deals  8.3 Co-development Deals  8.4 First-in-Class Programs not Involved in Licensing or Co-Development Deals 

9 Appendix 

For more information visit: http://www.researchandmarkets.com/research/35m9gq/frontier_pharma

Media Contact: Laura Wood, Senior Manager press@researchandmarkets.com   For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Weight Loss Surgery Foundation of America to Inclu...
S
Heidi Michele Davis is recognized by Continental W...